Ying Chang Huang

US Patent:

7855748, Dec 21, 2010

Filed:

Dec 3, 2007

Appl. No.:

11/949542

Inventors:

Giuseppe Rossi - Los Angeles CA, US
Laurent Blanquart - Westlake Village CA, US
Ying Huang - Newbury Park CA, US

Assignee:

AltaSens, Inc. - Westlake Village CA

International Classification:

H04N 5/225

US Classification:

348372, 348241, 327539

Abstract:

The claimed subject matter provides systems and/or methods that facilitate generating and/or maintaining low noise reference voltages for CMOS imaging System-on-Chip (iSoC) sensors. A primary reference voltage can be generated utilizing a low noise bandgap. Further, the primary reference voltage can be filtered via a low pass filter. The filtered, primary reference voltage can thereafter be distributed to a plurality of isolated domains. Each of the isolated domains can generate an independent set of reference voltages based upon the filtered, primary reference voltage. Moreover, subsets of these reference voltages can be employed by programmable digital to analog converters (DACs). Each of the reference voltages can be isolated from switching noise and/or clock glitches generated within each domain. Further, each DAC output can be buffered to have adequately low impedance with appropriate drive capability and requisite signal swing.

US Patent:

20220273617, Sep 1, 2022

Filed:

Feb 21, 2022

Appl. No.:

17/676684

Inventors:

Ying Huang - Arcadia CA, US
Bradley Tram Andresen - Upland CA, US
Jinghua Jeffrey Wang - Aradia CA, US
Vijay Kumar Nekkanti - Manchester MO, US
Ayaz Shahid - Pomona CA, US

International Classification:

A61K 31/403
A61P 9/10
A61P 9/12
A61P 9/04
A61P 35/00

Abstract:

A novel prophylactic therapy for cancer, as well as therapy against DNA damage, inflammation and immunosuppression involves the β-blocker carvedilol, which is a racemic mixture consisting of two enantiomers, S- and R-carvedilol, in 1:1 ratio. S-carvedilol is a β-blocker, with a highly potent antagonizing activity against the β-adrenergic receptors, which is the main mechanism for the drug's pharmacological activity in treatment of high blood pressure and heart failure. Carvedilol—the racemic mixture—prevents ultraviolet radiation induced skin cancer by attenuating DNA damage, reducing inflammation and reversing immunosuppression. The non-β-blocking enantiomer R-carvedilol exhibits the same cancer preventive efficacy as the racemic carvedilol, without disturbing the cardiovascular system. Both carvedilol and R-carvedilol prevent chemical carcinogen-induced lung cancer development and lung inflammation.

US Patent:

20160199345, Jul 14, 2016

Filed:

Sep 12, 2014

Appl. No.:

14/915965

Inventors:

- Pomona CA, US
Ying HUANG - Arcadia CA, US
Jinghua Jeffrey WANG - Arcadia CA, US
Ranadheer RAVULA - Atlanta GA, US
Zhi Jun WANG - Chino Hills CA, US

International Classification:

A61K 31/365
A61K 31/517
A61K 31/337
A61K 31/704

Abstract:

The invention provides compositions comprising wilforlide A for overcoming drug resistance in cancer therapy, particularly in the treatment of cancers which have exhibited resistance to treatment by chemotherapeutic drugs. Methods and compositions for treating a cancer are disclosed. The method administers to a patient in need thereof a combination of wilforlide A and a chemotherapeutic drug. Wilforlide A and chemotherapeutic drug are administered in a combined amount effective to treat the can cer. The cancer being treated is at least in part resistant to treatment by the chemotherapeutic drug alone.

US Patent:

20150238553, Aug 27, 2015

Filed:

Aug 19, 2013

Appl. No.:

14/422216

Inventors:

- Pomona CA, US
Ying Huang - Arcadia CA, US
Jinghua Jeffrey Wang - Arcadia CA, US
Ranadheer Ravula - Atlanta GA, US
Zhi Jun Wang - Chino Hills CA, US

International Classification:

A61K 36/37
A61K 39/395
A61K 31/517
A61K 31/337
A61K 31/704

Abstract:

The invention provides extracts and compositions derived from for overcoming drug resist-ance in cancer therapy. This invention relates to organic solvent extracts of and their use in cancer treatment, particularly in the treatment of cancers which have exhibited resistance to treatment by chemotherapeutic drugs. Methods of treating a cancer are disclosed. The method administers to a patient in need thereof a combination of (a) an organic solvent extract of and (b) a chemotherapeutic drug. The organic solvent extract of (a) and chemotherapeutic drug (b) are administered in a com-bined amount effective to treat the cancer. The cancer being treated is at least in part resistant to treatment by the chemotherapeutic drug (b) alone. Also disclosed are chemotherapeutic compositions comprising a combination of (a) an organic solvent extract of and (b) a chemotherapeutic drug, wherein (a) and (b) are administered in a combined amount effective to treat the cancer; and a pharmaceutically acceptable carrier.

US Patent:

20150157571, Jun 11, 2015

Filed:

Sep 10, 2012

Appl. No.:

14/240753

Inventors:

Maria Polikandritou Lambros - Pomona CA, US
Ying Huang - Pomona CA, US

Assignee:

WESTERN UNIVERSITY OF HEALTH SCIENCES - Pomona CA

International Classification:

A61K 9/127
A61K 31/704

Abstract:

The invention provides pharmaceutical compositions containing a vehicle for the targeted delivery of therapeutic and diagnostic agents for the treatment of hyperproliferative diseases. The targeting component of the vehicle is a cystine molecule that is coupled to the cargo component, which can be either a therapeutic or diagnostic agent or to a nanoparticle composition that contains the therapeutic agent or diagnostic. The invention also provides methods of treating hyperproliferative disorders by targeting hyperproliferative disease cells for the targeted delivery of a therapeutic or diagnostic agent.